Skip to main content
. 2023 Jul 25;12(15):4882. doi: 10.3390/jcm12154882

Figure 2.

Figure 2

This is a 69-year-old female with left breast invasive ductal carcinoma (ER+, PR+, and HER2+) who has received several rounds of HER2-targeted therapy, including ado-trastuzumab emtansine (TDM-1), and was on gemcitabine, trastuzumab, and pertuzumab therapy at the time of 89Zr-pertuzumab PET/CT. Tracer avidity was visualized in a known left supraclavicular lymph node metastasis (blue arrows), with SUVmax 5.1.